Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy

Bibliography

• Fang W, Li X, Jiang Q, et al. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med 2008;6:32
   PubMed Web of Science ®Google Scholar
• Fong KW, Chua EJ, Chua ET, et al. Patient profile and survival in 270 computer tomography-staged patients with nasopharyngeal cancer treated at the Singapore general hospital. Ann Acad Med Singapore 1996;25:341-6
   PubMedGoogle Scholar
• Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631-7
   PubMed Web of Science ®Google Scholar
• Wang TL, Tan YO. Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma. Ann Acad Med Singapore 1991;20:601-3
   PubMedGoogle Scholar
• Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 1994;5:87-9
   PubMed Web of Science ®Google Scholar
• Chi KH, Chan WK, Cooper DL, et al. A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil and leucovorin in nasopharyngeal carcinoma. Cancer 1994;73:247-52
   PubMed Web of Science ®Google Scholar
• Yeo W, Leung TW, Chan AT, et al. A phase II study combination of paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer 1998;34(13):2027-31
   PubMed Web of Science ®Google Scholar
• Tan EH, Khoo KS, Wee J, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 1999;10:235-7
   PubMed Web of Science ®Google Scholar
• Chua DT, Sham JS, Au GK. A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol 2005;41:589-95
   PubMed Web of Science ®Google Scholar
• Chua DT, Sham JS, Au GH. Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma. Am J Clin Oncol 2005;28:464-71
   PubMed Web of Science ®Google Scholar
• Wang CC, Chang JY, Liu TW, et al. Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma. Head Neck 2006;28:74-80
   PubMed Web of Science ®Google Scholar
• Peng PJ, Ou XQ, Chen ZB, et al. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy. Cancer Chemother Pharmacol 2013;72(2):323-8
   PubMed Web of Science ®Google Scholar
• Chen C, Wang FH, Wang ZQ, et al. Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 2012;48(11):1146-51
   PubMed Web of Science ®Google Scholar
• Siu LL, Czaykowshi PM, Tannock IF. Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx. J Clin Oncol 1998;16:2514-21
   PubMed Web of Science ®Google Scholar
• Boussen H, Cvitkovic E, Wendling JL, et al. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin and fluorouracil. J Clin Oncol 1991;9:1675-81
   PubMed Web of Science ®Google Scholar
• Taamma A, Fandi A, Azli N, et al. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann Oncol 1999;10:421-5
   PubMed Web of Science ®Google Scholar
• Hong R L, Sheen T S, Ko J Y, et al. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study. Br J Cancer 1999;80:1962-7
   PubMed Web of Science ®Google Scholar
• Hasbini A, Mahjoubi R, Fandi A, et al. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann Oncol 1999;10:421-5
   PubMed Web of Science ®Google Scholar
• Hang HQ, Cai QQ, Lin XB, et al. Preliminary result of multicenter clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi 2008;30:314-16
   PubMedGoogle Scholar
• Leong SS, Wee J, Rajan S, et al. Triplet combination of gemcitabine,paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer 2008;113:1332-7
   PubMed Web of Science ®Google Scholar
• Beldjilali KA, Benhadji A, Boukerche et al. First results of induction chemotherapy with cisplatin, docetaxel, and capecitabine for the treatment of nasopharyngeal carcinoma. J Clin Oncol 2009;27(15 Suppl):abstract 6045
   Web of Science ®Google Scholar
• Saragiotto DF, Maluf FC, Brandão LG, et al. Organ preservation using carboplatin, capecitabine, docetaxel, and radiotherapy in head and neck cancer: a phase II study. J Clin Oncol 2010;28(15 Suppl):abstract 5571
   Web of Science ®Google Scholar
• Lu YS, Chen DR, Tseng LM, et al. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy forlocally advanced breast cancer. Cancer Chemother Pharmacol 2011;67:1257-63
   PubMed Web of Science ®Google Scholar
• Kang YK, Ryu MH, Yoo C, et al. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2011;67:1435-43
   PubMed Web of Science ®Google Scholar
• Li JX, Lu TX, Huang Y, et al. Clinical features of 337 patients with recurrent nasopharyngeal carcinoma. Chin J Cancer 2010;29:82-6
   PubMedGoogle Scholar
• Lee AW, Foo W, Law SC, et al. Recurrent nasopharyngeal carcinoma: the puzzles of long latency. Int J Radiat Oncol Biol Phys 1999;44:149-56
   PubMed Web of Science ®Google Scholar
• Ciuleanu E, Irimie A, Ciuleanu TE, et al. Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study. Jpn J Clin Oncol 2007;37:477-81
   PubMed Web of Science ®Google Scholar
• Chua DT, Sham JS, Au GK, et al. Phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 2003;39:361-6
   PubMed Web of Science ®Google Scholar
• Chua D, Wei WI, Sham JS, et al. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn J Clin Oncol 2008;38:244-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Y, Huang PY, et al. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol 2008;61:33-8
   PubMed Web of Science ®Google Scholar
• Ngeow J, Lim WT, Leong S, et al. Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Ann Oncol 2011;22(3):718-22
   PubMed Web of Science ®Google Scholar
• Chua DT, Wei WI, Wong MP, et al. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck 2008;30:863-7
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao L, Huang P, et al. Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy. Cancer Chemother Pharmacol 2012;70:611-15
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;35:1695-704
   Google Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7
   PubMed Web of Science ®Google Scholar
• Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001;2:733-40
   PubMed Web of Science ®Google Scholar
• Chang JT, See LC, Liao CT, et al. Locally recurrent nasopharyngeal carcinoma. Radiother Oncol 2000;54:135-42
   PubMed Web of Science ®Google Scholar
• Yang TS, Ng KT, Wang HM, et al. Prognostic factors of locoregionally recurrent nasopharyngeal carcinoma—a retrospective review of 182 cases. Am J Clin Oncol 1996;19:337-43
   PubMed Web of Science ®Google Scholar
• Wang WY, Twu CW, Chen HH, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010;16:1016-24
   PubMed Web of Science ®Google Scholar
• Xin A, Wang FH, Ding PR, et al. Plasma epstein-barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 2011;117:3750-7
   PubMed Web of Science ®Google Scholar
• Han F, Zhao C, Huang SM, et al. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity- modulated radiotherapy. Clin Oncol (R Coll Radiol) 2011;24:569-76
   PubMed Web of Science ®Google Scholar
• Li Y-H, Wang FH, Jiang WQ, et al. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinom. Cancer Chemother Pharmacol 2008;62:539-44
   PubMed Web of Science ®Google Scholar
• Gao Y, Huang H-Q, Bai B, et al. Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy. Expert Opin Pharmacother 2013; In press
   PubMed Web of Science ®Google Scholar